LIEN

LIEN is an externally managed BDC that lends primarily to privately held cannabis operators, a niche the 10-K frames as 'highly complex and highly regulated' and 'underserved by other capital providers' — i.e. borrowers who pay up because banks won't touch them. The economics show it: FY2025 net income of $33.3M (+245.8% YoY) and diluted EPS of $1.46 put the stock at a 6.8x P/E, and equity of $303M against 22.8M shares implies book value near $13.29 versus a $9.98 price — roughly a 25% discount to NAV. Layer on $23.3M of dividends paid (~$1.02/share, a ~10% yield) and low-teens ROE (11.0%), and the setup is a cheap, high-income specialty lender rather than a broken one.

The balance sheet is unusually clean for a BDC: liabilities/equity of just 0.13x means the fund is barely levered, so the current return is being earned without the leverage most BDCs stack on — that is both a margin of safety and untapped upside if the manager deploys the balance sheet. The obvious offset is earnings quality: BDC net income runs through mark-to-market on the loan book, and this one is lumpy — $84.7M (FY2022) → $7.34M (FY2023) → $9.62M (FY2024) → $33.3M (FY2025). The 6.8x P/E flatters a number that includes unrealized swings, so the NAV discount and the dividend, not the headline P/E, are the real anchors of the thesis.